Abstract: A process for preparing an aminofunctional silicone emulsion is disclosed comprising: I) forming a mixture of 100 parts of a polydialkylsiloxane having a viscosity of at least 50,000 mm2/s at 23° C., and 0.1 to 100 parts of an aminofunctional organopolysiloxane, II) admixing to the mixture of step I 0.1 to 50 parts of a halide free quaternary ammonium surfactant, and a sufficient amount of water to form an emulsion, III) optionally, further shear mixing the emulsion; and IV) adding a sufficient amount of an acid of the formula H+X? to provide the emulsion with a neutral pH, where X is the same counter ion used in the quaternary ammonium surfactant.

Abstract: The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.

Abstract: A water soluble micronutrient composition that infuses vitamins and minerals into coffee and tea designed to maximize bio-absorption in consideration of pH levels, temperature and caffeine. The composition contains water-soluble and oil-soluble vitamins and minerals in bioavailable forms contained in a composition consisting of 1-50% of a vitamin blend with 1-35% of one or more minerals selected from the group consisting of calcium, magnesium, iron, zinc, copper and manganese, 10-55% citric acid, 5-35% of one or more alkali or alkaline earth metal bicarbonates or carbonates, 1-20% flavoring agent, 0.1-2% of a sweetening agent. When dissolved in liquid a specific amount of micronutrients are infused into the drink by way of a soluble, bioavailable form in the amount of approximately 25-100% of the US RDA of multiple vitamins and trace minerals along with a desired flavor to enhance the coffee, tea or other liquid.

Abstract: An oromucosally absorbable liquid composition for administration to a human patient comprises one liquid containing a pH-sensitive pharmaceutically active together with one or more optional suitable pharmaceutical excipients in a first compartment; and a second liquid at pH greater than 5 containing a buffer or alkaline components together with one or more optional suitable pharmaceutical excipients in a second distinct compartment; the first and second compartments maintaining separation of the first and second liquids during storage and allowing for mixing of the two liquids to form an oromucosally absorbable composition at the point of use

Abstract: Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent and (ii) an effective amount of the therapeutic agent, the flowable composition being capable of hardening to form a drug depot at a physiological temperature or as solvent contacts bodily fluid at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal.

Abstract: Provided herein are methods for treating an acute axonal injury by intranasally administering to a subject in need thereof an effective amount of a composition that includes a compound having the biological activity of inhibiting the effect of rapid stretch injury on neural stem-cell derived neurons. An example of such a compound is a Ret receptor ligand, such as a GDNF polypeptide. The compound is optionally associated with a delivery reagent. In one embodiment, the method further includes intranasally administering stem cells to the subject, such as neuronal stem cells or adipose-derived stem cells. Also provided herein are methods for decreasing impairment of long term potentiation of hippocampal synapses in a subject after an acute axonal injury.

Abstract: The invention provides methods for enhancing the delivery of therapeutic compounds to the eye of a subject by administering plasmin or derivatives thereof and the therapeutic compounds to the eye.

Abstract: The present disclosure relates to the use of polymers to coat bitter-tasting active pharmaceutical ingredients in a manner that masks the bitter taste of these compounds. Taste masked pharmaceutical formulations in which the particles of pharmaceutically active ingredients are coated with polymers or ion exchange resins are disclosed. The formulations provide taste masked pharmaceutical formulations in which the rapid disintegration of tablets is preserved. A method for preparing such coated particles in a fluidized bed coating process is disclosed. The polymer coating may include a combination of low molecular and high molecular weight water in-soluble polymers, plasticizer and fillers, which provides for a chewable dosage form having a pleasing taste thereby improving patient compliance.

Abstract: Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of the dosage form. The dosage forms find particular use in administration of acid-labile active agents such as proton pump inhibitors, and in treating gastric acid secretion such as gastro-esophageal reflux disease (GERD) and nocturnal acid breakthrough (NAB).

Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.

Abstract: The present invention comprises compositions and methods for providing antimicrobial compositions. The antimicrobial compositions comprise gel delivery vehicles comprising stabilized silver, wherein ionic silver is provided to a site for antimicrobial purposes. Methods of making and using such compositions are taught, including application of the silver-containing gel compositions to wounds, burns, abrasions, cuts, surgical incision, sites where skin or organ integrity has been breached, and other sites to supply an antimicrobial environment.

Abstract: The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-in-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyerlipidemia, and (8) is neither hyperallergenic nor vein irritating.

Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and/or internally.

Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.

Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.

Abstract: Nano-particles are molded in nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The nano-particles can include pharmaceutical compositions, taggants, contrast agents, biologic drugs, drug compositions, organic materials, and the like. The molds can be virtually any shape and less than 10 micron in cross-sectional diameter.

Abstract: Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery.

Abstract: The invention relates to a method for producing a nutritional and medicinal oral composition for veterinary use, comprising the following steps: a) providing cores of extruded products of complete feed, and b) coating the cores of extruded products of complete feed provided in step a) with at least one layer of a fatty material comprising at least one medicinal agent, said medicinal agent comprising (i) at least one pre-conditioned active substance in the form of a solution or a suspension of said active substance in an oily liquid, or (ii) at least one pre-conditioned active substance in the form of waxy granulates, at a temperature lower than 40° C.

Abstract: A process of producing an immunogenic particle includes mixing an aqueous solvent A wherein an antigen(s) is/are dissolved and a water-immiscible organic solvent B wherein an amphiphilic polymer(s) whose hydrophobic segment(s) is/are poly(hydroxy acid) is/are dissolved, to form a reversed-phase emulsion; and removing the solvent from the reversed-phase emulsion to obtain an antigen-adjuvant microparticle complex, wherein the aqueous solvent A and/or the water-immiscible organic solvent B contains a surfactant.

Abstract: Bacterial resistance to antibiotics is increasing worldwide creating a global threat. Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is a bacterial infectious disease that results in over one million deaths annually. The discovery outlined here involves a tablet composition for patient administration and subsequently a new paradigm in drug delivery vehicles in vivo and in vitro and is applied to existing TB antibiotics in order to increase their efficacy. The drug delivery system is a three component complex that is administered with the TB antibiotic or a combination of TB antibiotics. The components are a saccharide or saccharides, a transition metal ion or a combination of metal ions that can bind a nitrogen and/or oxygen atom(s), and a water soluble polymer capable of aggregating and enclosing the other constituents. The three component molecular delivery approach has demonstrated ability to overcome M. tuberculosis bacterial resistance to an existing antibiotic.

Abstract: The present invention relates to a method for preparing the sustained-release tablets via direct compression process, wet granulation process or dry granulation process to obtain the formulations. The present invention also provides a use of the sustained-release tablet formulation of pramipexole in the preparation of pharmaceutical compositions. A sustained release tablet formulation has advantages as follows: breaking out patent monopoly of the innovator preparation, drug dissolution release effects in vitro can be achieved and probably clinical treatment effects can also be accomplished consistent with that of the innovator preparation; abandoning anionic polymers used in the innovator preparation such that making the drug release and absorption not being influenced by the patent body's gastric pH values, in order to avoid the disadvantages of the innovator preparation.

Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.

Abstract: Described herein are pharmaceutical enteric soft capsules that do not contain gelatin as a film-forming polymer. In particular, compositions and methods for manufacturing enteric soft capsules comprising carrageenans as film forming polymers are disclosed.

Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.

Abstract: A composition comprising hydrophobic droplets coated by a shell and dispersed in a matrix and a consumable product comprising the composition are provided. The hydrophobic droplets comprise a hydrophobic compound, the shell comprises an irreversibly denatured protein, and the matrix comprises a protein, a starch, and a polysaccharide. Also provided are methods for preparing the composition and the consumable product.

Abstract: A storage stable L-menthol composition includes a tablet, caplet, capsule, or sachet dosage form. The dosage form has (a) a plurality of individual cores containing an L-menthol source and at least one pharmaceutical excipient and (b) a proteinaceous coating of a continuous film of proteinaceous material over the individual cores forming a plurality of proteinaceous coated individual cores. The film is effective to substantially prevent L-menthol in the L-menthol source from leaving the individual cores when stored at a temperature of 40 degrees C. and 75% relative humidity for at least 1 day. The dosage form contains an effective amount of the L-menthol source for treating a gastrointestinal disorder.

Abstract: The present invention relates to a veterinary zoo-technical drug delivery system (device) for the simultaneous release of two or more active substances, which system releases the active substances in a substantially constant ratio over a prolonged period of time. The drug delivery system can be in different forms, such as e.g. an implant, or a intravaginal device such as a helical coil, a spring or a ring.

Abstract: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmocokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a mRNA solution and a lipid solution, wherein the mRNA solution and/or the lipid solution are at a pre-determined temperature greater than ambient temperature.

Abstract: The present invention relates to the design and development of nanocapsule systems for the administration of active substances, wherein the nanocapsules of the system have a mean diameter less than 1 ?m and are characterized by comprising (a) a protamine shell, (b) an oily core, and one or more surfactants characterized by having a hydrophilic-lipophilic ratio greater than 8, provided that said surfactant is not a phospholipid.

Abstract: A device and method for moving a membrane into contact and out of contact with the surface of a skin of a patient. The membrane contains at least one active pharmaceutical ingredient (API) and is configured to release the API to the patient when the membrane is in contact with the skin. The device includes components which control the timing of the movement of the membrane based on intended drug delivery profiles. The device may control the amount of surface area of the membrane contacting the skin or the pressure of the membrane on the skin to additionally adjust the drug delivery profile. The membrane may be on a translating platform which moves to a down position where the membrane is in contact with the skin or to an up position where the membrane is not in contact with the skin.

Abstract: This invention provides a transdermal patch comprising a) a backing layer; b) a liner; c) optionally, a highly porous membrane; and d) a pharmaceutical composition comprising: (i) optionally, a pressure sensitive adhesive in an amount of up to about 95 wt % of the pharmaceutical composition, (ii) laquinimod in an amount of about 0.1-20 wt % of the pharmaceutical composition, and (iii) optionally, one or more permeation enhancers in a total amount of up to about 70 wt % of the pharmaceutical composition. This invention also provides a method for delivering laquinimod across the skin of the subject and for treating a human subject afflicted with a form of multiple sclerosis comprising administering to the skin of the subject a transdermal patch as described herein. This invention further provides a transdermal patch as described herein for use in treating a human subject afflicted with a form of multiple sclerosis.

Abstract: The present invention is related to a powderous composition which comprises lutein and which is used in infant food formulations or premixes for infant food formulations.

Abstract: Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.

Abstract: The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections.

Abstract: The present invention provides the use of a compound of Formula A for the manufacture of a medicament in the treatment of tumor necrosis factor (TNF)-related diseases, and a method for treating a TNF-related disease, said method comprising administering to a subject in need a therapeutically effective amount of a compound of Formula A.

Abstract: This invention is directed to compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.

Abstract: Disclosed is a method for inhibiting cancer cell growth in a subject in need thereof, comprising administering to the subject an effective amount of a compound from Antrodia camphorata, wherein the compound is represented by formula (I): wherein R1 is a hydrogen atom or an acetyl group; and a method of inhibiting cancer cell growth by using the compound, the cancer is selected from the group consisting of lung cancer, colon cancer, prostate cancer, liver cancer and breast cancer.

Abstract: The subject invention provides a method for promoting wound healing and preventing an infection or treating an existing infection with negative pressure wound therapy, said method comprising the steps of providing a sterile disinfectant composition comprising an active agent comprising chlorhexidine and administering the sterile disinfectant composition to the wound site prior to, during and/or following negative pressure wound therapy. The subject invention also provides a kit comprising the sterile disinfectant composition and, optionally, devices for administration of the sterile disinfection composition to the site with negative pressure wound therapy.

Abstract: Provided are an agent for imparting ceramide-like function, an agent for reinforcing skin barrier function, a moisturizing agent and a skin drug for external use. The agent for imparting ceramide-like function comprises as an effective ingredient a derivative of succinic acid diamide represented by the following formula (1): [wherein R1 and R2 each independently represents a hydroxyalkyl group of from 1 to 6 carbon atoms, R3 represents a group: —CH2CH2CH2CH2—R4 or a group: —CH2CH?CHCH2—R4 (wherein R4 represents an alkyl group of from 8 to 26 carbon atoms)].

Abstract: Disclosed herein are methods for identifying compounds that enhance base excision repair, as well as compounds identified thereby and methods of using such compounds in the interception of malignancy, i.e. the prevention of progression of a disease from a state of susceptibility to active disease. Exemplified compounds are acetohexamide and related compounds, as well as benserazide and analogs thereof. Exemplified malignancies are those of human breast cells carrying mutations, in particular, SUM149 cells and HCC1937 cells, which cells carry BRCA1 mutations.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: A method for treating skin that is subject to an energy injury including the application of concentrated l-lactic acid to the injury area during the inflammatory response of the skin. Reapplication is shown to further reduce the inflammatory symptoms and improve healing time. The concentration of approximately ten percent by weight with around 2.34 pH is proven to be ideal to impede the skin's inflammatory response for sunburn and elevated temperature thermal burns and prevent associated cellular damage compared to untreated sunburns.

Abstract: Disclosed herein are compositions and methods that are useful for inducing the development of regulatory T cells (Treg). Such compositions and methods are useful for treating inflammatory conditions and in particular inflammatory conditions affecting the gastrointestinal tract of a subject. In certain embodiments, the present inventions generally relate to short chain fatty acids and the discovery that such short chain fatty acids may be used to treat and/or prevent inflammatory conditions by enhancing the size and immune function of a subject's endogenous Treg population.

Abstract: The subject invention provides a method of reducing the presence of toxic intermediates of amyloidosis from islet amyloid polypeptide (IAPP) in a patient, comprising administering a compound to the patient a compound having the structure: (Formula 1) wherein R1 and R2 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, or R1 and R2 are linked so as to form a cyclopropyl cyclobutyl, cyclopentyl, or cyclohexyl ring; wherein R3, R4, R5, R6 are each independently hydrogen, fluorine or chlorine; and wherein R7 is hydrogen, phenyl, fluorine, chlorine, bromine, hydroxyl, amine, carboxylic acid, C1-C6 alkyl carboxylate, amide, methyl, ethyl, butyl, pentyl, hexyl, or a pharmaceutically acceptable salt or ester thereof, so as to thereby reduce the presence of toxic intermediates of amyloidosis from islet amyloid polypeptide (IAPP) in the patient.

Abstract: Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat diabetes, and methods for preparing activated fatty acids are provided herein.

Abstract: The present invention provides a method of extracting naturally occurring oil bodies comprising obtaining material containing naturally occurring oil bodies, recovering the oil bodies in a wet preparation and drying the oil bodies; and dried oil bodies obtained by the method and uses thereof.

Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.

Abstract: The present technology generally relates to a method for treating a subject, comprising administering to the subject a composition comprising a depot of disulfiram, wherein the composition is administered to the lumen of the gastrointestinal (GI) tract, the wall of the GI tract or an area that is substantially drained by the hepatic portal circulation or lacteals/lymphatic system.